US2014221608A1PendingUtilityA1

Acid-cleavable linkers exhibiting altered rates of acid hydrolysis

Assignee: DU PONTPriority: Nov 15, 2010Filed: Apr 15, 2014Published: Aug 7, 2014
Est. expiryNov 15, 2030(~4.3 yrs left)· nominal 20-yr term from priority
C07K 5/1021C07K 14/435C07K 2319/50C07K 2319/00C07K 7/06C07K 1/12C12P 21/06C07K 2319/01C12N 15/62
61
PatentIndex Score
0
Cited by
0
References
0
Claims

Abstract

An acid-cleavable peptide linker comprising aspartic acid and proline residues is disclosed. The acid-cleavable peptide linker provides an altered sensitivity to acid-hydrolytic release of peptides of interest from fusion peptides of the formula PEP1-L-PEP2. The inventive linker, L, is described in various embodiments, each of which provides substantially more rapid acid-release of peptides of interest than does a single aspartic acid-proline pair. In an additional aspect, a method of increasing the stability of an acid cleavable linkage to acid hydrolysis is also provided.

Claims

exact text as granted — not AI-modified
1 . A method of preparing at least one peptide of interest (“POI”) from a fusion peptide comprising at least one POI, comprising:
 a) providing a recombinant cell synthesizing the fusion peptide of  claim 21   
 b) contacting the fusion peptide with a solution of sufficiently acidic pH so that linker L is cleaved, and 
 c) isolating the at least one POI. 
 
     
     
         2 . (canceled) 
     
     
         3 . The method of  claim 1  wherein the recombinant cell is a recombinant microbial cell. 
     
     
         4 . The method of  claim 3  wherein the recombinant microbial cell is a recombinant yeast cell. 
     
     
         5 . The method of  claim 3  wherein the recombinant microbial cell is a recombinant bacterial cell. 
     
     
         6 . The method of  claim 1  wherein the acid-cleavable linker is cleaved by incubating the fusion peptides at a pH in the range from about pH 1 to about pH 4. 
     
     
         7 . The method of  claim 1  wherein the acid-cleavable linker is cleaved by incubating the fusion peptides at a pH in the range from about pH 2 to about pH 4. 
     
     
         8 . The method of  claim 1  wherein the acid-cleavable linker is cleaved by incubating the fusion peptides at a pH in the range from about pH 3 to about pH 4. 
     
     
         9 . The method of  claim 1  wherein the acid-cleavable linker is cleaved by incubating the fusion peptides at a pH of about 4. 
     
     
         10 . The method of  claim 1  wherein the acid-cleavable linker is cleaved by incubating the fusion peptides at a temperature of about 40° C. to about 90° C. 
     
     
         11 . The method of  claim 1  wherein the acid-cleavable linker is cleaved by incubating the fusion peptides at a temperature of about 50° C. to about 80° C. 
     
     
         12 . The method of  claim 1  wherein the acid-cleavable linker is cleaved by incubating the fusion peptides at a temperature of about 60° C. to about 70° C. 
     
     
         13 . The method of  claim 1  wherein the acid-cleavable linker is cleaved by incubating the fusion peptides at a temperature of about 60° C. 
     
     
         14 . The method of  claim 1  wherein the acid-cleavable linker is cleaved by incubating the fusion peptides at a pH of about pH 2 to about pH 4 using a temperature of about 50° C. to about 80° C. 
     
     
         15 . The method of  claim 1 , wherein PEP1 and PEP2 are both POIs. 
     
     
         16 . The method of  claim 15 , wherein the fusion peptide is soluble in the recombinant cell. 
     
     
         17 . The method of  claim 15 , wherein the fusion peptide is insoluble in the recombinant cell. 
     
     
         18 . The method of  claim 17 , wherein cleaving the fusion peptide under acidic conditions renders the at least one POI soluble. 
     
     
         19 . The method of  claim 1 , wherein either PEP1 or PEP2 of the fusion peptide comprises an inclusion body tag, thereby comprising a non-POI portion of the fusion peptide. 
     
     
         20 . The method of  claim 19 , wherein the non-POI portion remains insoluble after cleaving the fusion peptide. 
     
     
         21 . A fusion peptide comprising two peptides separated by an acid-cleavable linker according to the following general formula:
   PEP1-L-PEP2   
       wherein,
 a) PEP1 and PEP2 are independently functional peptides wherein at least one is a peptide of interest (“POI”); and 
 b) L is an acid-cleavable linker comprising a peptide selected from the group consisting of: 
 
       
         
           
                 
                 
               
                     
                   (SEQ ID NO: 1) 
                 
                     
                   A. DPDP, 
                 
                     
                     
                 
                     
                   (SEQ ID NO: 2) 
                 
                     
                   B. DPDPDP, 
                 
                     
                   and 
                 
                     
                     
                 
                     
                   (SEQ ID NO: 3) 
                 
                     
                   C. DPDPDPDP, 
                 
             
                
                
                
                
                
                
                
                
                
               
            
           
         
       
       wherein D is aspartic acid and P is proline. 
     
     
         22 . (canceled) 
     
     
         23 . The fusion peptide of  claim 21  wherein PEP1 and PEP2 are nonidentical. 
     
     
         24 . The fusion peptide of  claim 23 , wherein the fusion peptide is soluble in a recombinant cell. 
     
     
         25 . The fusion peptide of  claim 24  wherein the recombinant cell is a recombinant microbial cell. 
     
     
         26 . The fusion peptide of  claim 25  wherein the recombinant microbial cell is a recombinant bacterial cell. 
     
     
         27 . The fusion peptide of  claim 25  wherein the recombinant microbial cell is a recombinant yeast cell. 
     
     
         28 . The fusion peptide of  claim 23 , wherein the fusion peptide is insoluble in a recombinant cell. 
     
     
         29 . The fusion peptide of  claim 28  wherein the recombinant cell is a recombinant microbial cell. 
     
     
         30 . The fusion peptide of  claim 29  wherein the recombinant microbial cell is a recombinant yeast cell. 
     
     
         31 . The fusion peptide of  claim 30  wherein the recombinant microbial cell is a recombinant bacterial cell. 
     
     
         32 . The fusion peptide of  claim 23  wherein either of PEP1 or PEP2 comprises an inclusion body tag (“IBT”). 
     
     
         33 . The fusion peptide of  claim 32  wherein the fusion peptide is present in inclusion bodies. 
     
     
         34 . The fusion peptide of  claim 23  wherein the acid-cleavable linker is cleaved by incubation at a pH in the range from about pH 1 to about pH 4. 
     
     
         35 . The fusion peptide of  claim 23  wherein the acid-cleavable linker is cleaved by incubating at a temperature of about 40° C. to about 90° C. 
     
     
         36 . The fusion peptide of  claim 35  wherein the acid-cleavable linker is cleaved by incubating at a temperature of about 50° C. to about 80° C. 
     
     
         37 . The fusion peptide of  claim 36  wherein the acid-cleavable linker is cleaved by incubating at a temperature of about 60° C. to about 70° C. 
     
     
         38 . The fusion peptide of  claim 23  wherein the acid-cleavable linker is cleaved by incubating at a pH of about pH 2 to about pH 4 and at a temperature of about 50° C. to about 80° C. 
     
     
         39 . A recombinant cell expressing a fusion protein having the structure
   PEP1-L-PEP2   wherein,   i) PEP1 and PEP2 are independently functional peptides, one of which is a POI; and   ii) L is an acid-cleavable linker comprising a peptide selected from the group consisting of:   
       
         
           
                 
                 
               
                     
                   (SEQ ID NO: 1) 
                 
                     
                   A. DPDP, 
                 
                     
                     
                 
                     
                   (SEQ ID NO: 2) 
                 
                     
                   B. DPDPDP, 
                 
                     
                   and 
                 
                     
                     
                 
                     
                   (SEQ ID NO: 3) 
                 
                     
                   C. DPDPDPDP, 
                 
             
                
                
                
                
                
                
                
                
                
               
            
           
         
         wherein D is aspartic acid and P is proline; and 
         wherein the expressed fusion peptide is present in the recombinant cell. 
       
     
     
         40 . (canceled) 
     
     
         41 . The recombinant cell of  claim 39  wherein the recombinant cell is a recombinant microbial cell. 
     
     
         42 . The recombinant cell of  claim 41  wherein the recombinant cell is a recombinant bacterial cell. 
     
     
         43 . The recombinant cell of  claim 41  wherein the recombinant cell is a recombinant microbial cell is a recombinant yeast cell. 
     
     
         44 . An acid-cleavable peptide linker comprising a peptide selected from the group consisting of: 
       
         
           
                 
                 
               
                     
                   (SEQ ID NO: 1) 
                 
                     
                   A. DPDP, 
                 
                     
                     
                 
                     
                   (SEQ ID NO: 2) 
                 
                     
                   B. DPDPDP, 
                 
                     
                   and 
                 
                     
                     
                 
                     
                   (SEQ ID NO: 3) 
                 
                     
                   C. DPDPDPDP, 
                 
             
                
                
                
                
                
                
                
                
                
               
            
           
         
         wherein D is aspartic acid and P is proline. 
       
     
     
         45 - 46 . (canceled)

Join the waitlist — get patent alerts

Track US2014221608A1 — get alerts on status changes and closely related new filings.

We store only your email — no account needed. See our privacy policy.